All Episodes
Power to the Patients — 54 episodes
How Neuroplasticity Is Shaping the Next Generation of Psychiatric Medicines
70% Remission for Postpartum Depression? The Psychedelic Breakthrough
Why Psychiatry Is Finally Breaking Free From Dopamine
Precision Medicine Got Kidney Disease Wrong—Until Now
Why Dr. Ken Sharlin Believes Most Neurological Diseases Are Reversible
Why Serotonin Isn’t Outdated, Our Thinking Is
Who Really Protects Patients in Clinical Trials? With Dr. Lara Shirikjian
Turning Pain Into Progress: How Sonia Prashar Built a Mission Around Mental Health
The Synapse Secret: How One Molecule Normalized Brain Activity in Fragile X Patients
Beyond Dopamine: Why Traditional Schizophrenia Treatments Miss 50% of Patient Needs
The 20-Year Industry Secret: Redefining Neurodegenerative Treatment
One Mechanism, Three Conditions: A New Direction in Neurological Treatment
Why Traditional Psychedelics Miss 90% of Neurology Patients - And The Solution
Inside the ALS Breakthrough: 20-Year Journey to FDA Approval with Dr. Joseph Palumbo
Why Clinical Trial Speed Kills Success - And What Top Sponsors Do Instead ft. Steve Brannan
Dr. Anantha Shekhar on the Convergence of Psychiatry, Neurology, and the Next Era of Brain Medicine
Ram Mukunda, CEO of IGC Pharma, on Innovation and Hope in Alzheimer’s Care
Brandon Bentzley, CSO and Co-founder of Magnus Medical, on Precision Psychiatry and Rewiring Depression
Sarah MacCallum & Melissa Gaines- Clinical Operations Leaders at Annovis Bio
Daniel O'Connell, CEO of Acumen Pharmaceuticals, on Oligomers, Innovation, and Hope in Alzheimer’s
Michael Gold, Chief R&D Officer at Compass Pathways
Matthew Leoni, CMO of Merida Biosciences, on Navigating the Challenges and Opportunities in Neuroscience Drug Development
Gerard Sanacora, Professor at Yale, on glutamate, GABA, and the next era of depression treatment
Backing Breakthroughs in Psychedelics
Joel Raskin, CMO of Arrivo Bio talks about unlocking the future of psychiatry
Dr. Jerry Rosenbaum & Dr. Sharmin Ghaznavi: Mass General Center on the Neuroscience of Psychedelics
Spyros Papapetropoulos, CEO of Neuphoria
Steve Gourlay, CEO of Actinogen
Boehringer Ingelheim: Christine Sakdalan and Mike Jablonski talk precision psychiatry
John Krystal: Advancing Ketamine Research & Psychiatry at Yale
Next-Gen Treatments for Anxiety and Depression Disorders
Precision Psychiatry and Emerging Technologies
From Culture to Care: The Framework of Patient Centricity
Unraveling Mysteries of the Brain Through Neuroscience Research
Harnessing Precision Medicine to Redefine Psychiatric Treatment
Breaking New Ground with Psilocybin
Bringing the Consumer Experience to Clinical Research
A New Frontier of Psychedelic Therapies
A Pragmatic Approach to Psychedelic Drug Development
Building a High Recruiting Site in Alzheimer's
Why Beckley Psytech is Developing the Next Generation of Psychedelics
The Mental Health Epidemic in Rural America
Going All In on Psilocybin for Depression
Psychedelics and the Future of Anxiety Relief
AliveAndKickn: Raising Awareness about Lynch Syndrome
Empowering Patients through Digital Platforms in Clinical Trials with Sasha Sinclair
Integrating Patient Experience in Clinical Trials with Farah Meghji
Patient-first Approaches in Clinical Trials with Megan Liles
Patient-informed clinical trial development with Victoria DiBiaso, VP & Global Head Patient Informed Development & Health Value Translation at Sanofi
Integrating patient centricity culturally and operationally, with Dr. Anthony Yanni, Sr. VP and Head of Patient Centricity at Astellas
Exploring Technology and Patient Engagement in Clinical Trials with Bryan Wylie
Patient advocacy with Stephanie E. Saville, Foundation Manager for the Pediatric Retinal Research Foundation
Oncology trial strategy with Deb Kientop, VP Clinical Operations at Deka Biosciences
Patient-centered design with Scott Schliebner, former SVP at ICON